Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
After quietly plowing the arid cancer vaccine field for a decade, a low profile Swiss biotech is throwing itself in the ring as a player to watch in the frenetic race to extend the benefits of immunotherapies to solid tumors.
Co-founded by biotech vet Bernard Mach — who was involved in the creation of Biogen and Novimmune — and his son Nicolas, MaxiVAX is laser-focused on developing a two-part cancer vaccine that activates the immune system to attack cancer. And it has been awarded a €2.785 million ($3.07 million) grant from the European Commission — on top of CHF 5 million ($5.01 million) from a Series B2 round — to push through a Phase II study in head and neck cancer in Switzerland and kick off a US study for an undisclosed rare tumor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.